| Literature DB >> 34226892 |
Toheeb Mustapha1, Jagdish Khubchandani1, Nirbachita Biswas1.
Abstract
Entities:
Year: 2021 PMID: 34226892 PMCID: PMC8241692 DOI: 10.1016/j.bbih.2021.100289
Source DB: PubMed Journal: Brain Behav Immun Health ISSN: 2666-3546
A Global Assessment of COVID-19 Vaccination Hesitancy Rates and Reasons for Hesitancy in Students and Trainees of Healthcare Professions.
| Author/Data Collected | Country | Sample size (N) | Hesitancy Rate | Reasons for Vaccination Hesitancy and Enablers of COVID-19 Vaccine Uptake |
|---|---|---|---|---|
| Kuwait | 592∗ | 24.2% | ∗∗Reasons: Social stigma about vaccines and lower education level. | |
| Italy | 274∗ | 7.3% | ∗∗Reasons: Lesser understanding of preventive measures; lower concerns about the pandemic, COVID cases & deaths. | |
| Germany | 208∗ | 20.2% | ∗∗Reason: Low trust in the government, media, and in the German healthcare system. | |
| Turkey | 694∗ | 9.7% | ∗∗Reasons: Concerns about vaccine side effects and effectiveness; trust in one’s immune system/ vaccine not needed. | |
| USA | 1,029∗ | 21.6% | Reasons: Concerns about safety, side effects, rapid development, and mistrust in the vaccine development process. | |
| USA | 167 | 23% | Reasons: Concerns about safety, efficacy, side effects; rapid development/ political influence, mistrust in govt. agencies. | |
| Israel | 628 | 17.8% | Reasons: Concerns about safety and side effects, lower perceived risk of COVID-19, fear of needles, lack of time. | |
| Poland | 239∗ | 9.6% | ∗∗Reasons: Concerns about vaccine safety and effectiveness. | |
| USA | 408 | 35.5% | Reasons: Concerns about effectiveness/side effects, rapid vaccine development, insufficient information about vaccine, mistrust in regulatory agencies, and politicization. | |
| Poland | 687∗ | 4.1% | ∗∗Reasons: Concerns about vaccines causing autism, fever and malaise, long-term complications, side effects. | |
| GR, AB, CY, SP, IT, CZ, KO | 2,249 | 22.2% | Reasons: Concerns about vaccine safety, efficacy, and effectiveness. Lower knowledge about COVID-19 & vaccines. | |
| CH, IN, ID, SG, VI, BH | 19∗ | 5.3% | ∗∗Reasons: Concerns about vaccine allergy and side effects, financial costs, and contracting the virus from the vaccine. | |
| USA | 245 | 44.5% | Reasons: Concerns about side effects, rapid development of vaccine, mistrust in regulatory agencies, and politicization. | |
| Slovenia | 624∗ | 33.5% | ∗∗Reasons: Concerns about vaccine safety and side effects, mistrust in government, negative attitudes about vaccines. | |
| Egypt | 2,133 | 19.4% | Reasons: Concerns about vaccine safety, efficacy, side effects, mistrust of vaccination source, lack of information. | |
| 22 countries | 6639 | 13.9% | Reasons: Concerns about side effects, safety, social media impact, lack of information, anti-vaccination belief/attitudes. | |
| Uganda | 600 | 62.7% | Reasons: Concerns about side effects, safety, effectiveness; misinformation on vaccine; trust in personal immunity. | |
| India | 1068 | 10.6% | Reasons: Concerns about vaccine safety & efficacy, rapid development, mistrust in government/public health agencies. | |
| China | 1488 | 15.6% | Reasons: Concerns about safety and side effects, rapid vaccine development, lower perceived risk of COVID infection. | |
| Overall | 39 countries | 19,991 | 18.9% | Top 3 Reasons: Concerns about safety, side effects, and efficacy. |
∗indicates that the participants were the part of a larger sample ∗∗ indicates reasons and enablers for the whole sample. A total of 19 studies with 19,991 participants have been included in this Table. Data collection month instead of publication date for the study have been arranged in chronological order in the table. The overall prevalence of vaccine hesitancy was estimated from the included studies with 95% confidence intervals using random-effects modeling.